메뉴 건너뛰기




Volumn 19, Issue 4, 2010, Pages 264-269

New opportunities in the treatment of cognitive impairments associated with schizophrenia

Author keywords

CIAS; CNTRICS; cognition; MATRICS; Schizophrenia; TURNS

Indexed keywords


EID: 77957885222     PISSN: 09637214     EISSN: 14678721     Source Type: Journal    
DOI: 10.1177/0963721410378359     Document Type: Article
Times cited : (9)

References (27)
  • 2
    • 57649140590 scopus 로고    scopus 로고
    • Removing obstacles in neuroscience drug discovery: The future path for animal models
    • A summary of task force discussions regarding the status and role of animal models in drug discovery
    • Markou, M., Chiamulera, C., Geyer, M.A., Tricklebank, M., & Steckler, T. (2009). Removing obstacles in neuroscience drug discovery: The future path for animal models. Neuropsychopharmacology Reviews, 34, 74-89. A summary of task force discussions regarding the status and role of animal models in drug discovery.
    • (2009) Neuropsychopharmacology Reviews , vol.34 , pp. 74-89
    • Markou, M.1    Chiamulera, C.2    Geyer, M.A.3    Tricklebank, M.4    Steckler, T.5
  • 4
    • 57749178648 scopus 로고    scopus 로고
    • Selecting paradigms from cognitive neuroscience for translation into use in clinical trials: Proceedings of the third CNTRICS meeting
    • Barch, D.M., Carter, C.S., Arnsten, A., Buchanan, R.W., Cohen, J.D., Geyer, M.,et al.(2009). Selecting paradigms from cognitive neuroscience for translation into use in clinical trials: Proceedings of the third CNTRICS meeting. Schizophrenia Bulletin, 35, 109-114.
    • (2009) Schizophrenia Bulletin , vol.35 , pp. 109-114
    • Barch, D.M.1    Carter, C.S.2    Arnsten, A.3    Buchanan, R.W.4    Cohen, J.D.5    Geyer, M.6
  • 5
    • 20844439028 scopus 로고    scopus 로고
    • A summary of the FDA-NIMH-MATRICS workshop on clinical trial design for neurocognitive drugs for schizophrenia
    • Buchanan, R.W., Davis, M., Goff, D., Green, M.F., Keefe, R.S., Leon, A.C.,et al.(2005). A summary of the FDA-NIMH-MATRICS workshop on clinical trial design for neurocognitive drugs for schizophrenia. Schizophrenia Bulletin, 31, 5-19.
    • (2005) Schizophrenia Bulletin , vol.31 , pp. 5-19
    • Buchanan, R.W.1    Davis, M.2    Goff, D.3    Green, M.F.4    Keefe, R.S.5    Leon, A.C.6
  • 6
    • 34548321168 scopus 로고    scopus 로고
    • Recent advances in the development of novel pharmacological agents for the treatment of cognitive impairments in schizophrenia
    • Buchanan, R.W., Freedman, R., Javitt, D.C., Abi-Dargham, A., & Lieberman, J.A. (2007). Recent advances in the development of novel pharmacological agents for the treatment of cognitive impairments in schizophrenia. Schizophrenia Bulletin, 33, 1120-1130.
    • (2007) Schizophrenia Bulletin , vol.33 , pp. 1120-1130
    • Buchanan, R.W.1    Freedman, R.2    Javitt, D.C.3    Abi-Dargham, A.4    Lieberman, J.A.5
  • 7
    • 34548348724 scopus 로고    scopus 로고
    • Cognitive neuroscience-based approaches to measuring and improving treatment effects on cognition in schizophrenia: The CNTRICS initiative
    • Carter, C.S., & Barch, D.M. (2007). Cognitive neuroscience-based approaches to measuring and improving treatment effects on cognition in schizophrenia: The CNTRICS initiative. Schizophrenia Bulletin, 33, 1131-1137.
    • (2007) Schizophrenia Bulletin , vol.33 , pp. 1131-1137
    • Carter, C.S.1    Barch, D.M.2
  • 8
    • 77957877198 scopus 로고    scopus 로고
    • Cognitive neuroscience approaches to treatment development of impaired cognition in schizophrenia: Proceedings of the First Meeting of the CNTRICS Initiative [Special issue]
    • Carter, C.S., & Barch, D.M. (Eds.)
    • Carter, C.S., & Barch, D.M. (Eds.). (2008). Cognitive neuroscience approaches to treatment development of impaired cognition in schizophrenia: Proceedings of the First Meeting of the CNTRICS Initiative [Special issue]. Biological Psychiatry, 64(1).
    • (2008) Biological Psychiatry , vol.64 , Issue.1
  • 9
    • 44749086732 scopus 로고    scopus 로고
    • Identifying cognitive mechanisms targeted for treatment development in schizophrenia: An overview of the first meeting of the Cognitive Neuroscience Treatment Research to Improve Cognition in Schizophrenia Initiative
    • Carter, C.S., Barch, D.M., Buchanan, R.W., Bullmore, E., Krystal, J.H., Cohen, J.,et al.(2008). Identifying cognitive mechanisms targeted for treatment development in schizophrenia: An overview of the first meeting of the Cognitive Neuroscience Treatment Research to Improve Cognition in Schizophrenia Initiative. Biological Psychiatry, 64, 4-10.
    • (2008) Biological Psychiatry , vol.64 , pp. 4-10
    • Carter, C.S.1    Barch, D.M.2    Buchanan, R.W.3    Bullmore, E.4    Krystal, J.H.5    Cohen, J.6
  • 10
    • 0141889787 scopus 로고    scopus 로고
    • Breaking the log-jam in treatment development for cognition in schizophrenia: NIMH perspective
    • Fenton, W.S., Stover, E.L., & Insel, T.R. (2003). Breaking the log-jam in treatment development for cognition in schizophrenia: NIMH perspective. Psychopharmacology, 169, 365-366.
    • (2003) Psychopharmacology , vol.169 , pp. 365-366
    • Fenton, W.S.1    Stover, E.L.2    Insel, T.R.3
  • 11
    • 26444539074 scopus 로고    scopus 로고
    • Developing predictive animal models and establishing a preclinical trials network for assessing treatment effects on cognition in schizophrenia
    • Floresco, S., Geyer.M.A., Gold,. L.H.& Grace, A.A. (2005). Developing predictive animal models and establishing a preclinical trials network for assessing treatment effects on cognition in schizophrenia. Schizophrenia Bulletin, 31, 888-894.
    • (2005) Schizophrenia Bulletin , vol.31 , pp. 888-894
    • Floresco, S.1    Geyer, M.A.2    Gold, L.H.3    Grace, A.A.4
  • 12
    • 77957866393 scopus 로고    scopus 로고
    • New approaches to assessing and improving cognition in schizophrenia [Special issue]
    • Geyer, M.A. (Ed.)
    • Geyer, M.A. (Ed.). (2005). New approaches to assessing and improving cognition in schizophrenia [Special issue]. Schizophrenia Bulletin, 31(4).
    • (2005) Schizophrenia Bulletin , vol.31 , Issue.4
  • 13
    • 26444552259 scopus 로고    scopus 로고
    • New approaches to measurement and treatment research to improve cognition in schizophrenia
    • Geyer, M.A., & Heinssen, R. (2005). New approaches to measurement and treatment research to improve cognition in schizophrenia. Schizophrenia Bulletin, 31, 806-809.
    • (2005) Schizophrenia Bulletin , vol.31 , pp. 806-809
    • Geyer, M.A.1    Heinssen, R.2
  • 14
    • 3142680754 scopus 로고    scopus 로고
    • MATRICS: Measurement and treatment research to improve cognition in schizophrenia [Special issue]
    • Geyer, M.A., & Tamminga, C.A. (Eds.)
    • Geyer, M.A., & Tamminga, C.A. (Eds.). (2004a). MATRICS: Measurement and treatment research to improve cognition in schizophrenia [Special issue]. Psychopharmacology, 174(1).
    • (2004) Psychopharmacology , vol.174 , Issue.1
  • 15
    • 3142680754 scopus 로고    scopus 로고
    • Measurement and treatment research to improve cognition in schizophrenia: Neuropharmacological aspects
    • Geyer, M.A., & Tamminga, C.A. (2004b). Measurement and treatment research to improve cognition in schizophrenia: Neuropharmacological aspects. Psychopharmacology, 174, 1-2.
    • (2004) Psychopharmacology , vol.174 , pp. 1-2
    • Geyer, M.A.1    Tamminga, C.A.2
  • 16
    • 0010411289 scopus 로고    scopus 로고
    • The role of preclinical models in the development of psychotropic drugs
    • In K.L. Davis, D. Charney, J.T. Coyle, & C. Nemeroff (Eds.), Philadelphia: Lippincott Williams & Wilkins
    • Geyer, M.A., & Markou, A. (2002). The role of preclinical models in the development of psychotropic drugs. In K.L. Davis, D. Charney, J.T. Coyle, & C. Nemeroff (Eds.) Neuropsychopharmacology: The Fifth Generation of Progress (pp. 445-455). Philadelphia: Lippincott Williams & Wilkins.
    • (2002) Neuropsychopharmacology: The Fifth Generation of Progress , pp. 445-455
    • Geyer, M.A.1    Markou, A.2
  • 17
    • 0029918481 scopus 로고    scopus 로고
    • What are the functional consequences of neurocognitive deficits in schizophrenia?
    • Green, M.F. (1996). What are the functional consequences of neurocognitive deficits in schizophrenia? American Journal of Psychiatry, 153, 321-330.
    • (1996) American Journal of Psychiatry , vol.153 , pp. 321-330
    • Green, M.F.1
  • 18
    • 7544250144 scopus 로고    scopus 로고
    • The MATRICS initiative: Developing a consensus cognitive battery for clinical trials
    • Green, M.F., & Nuechterlein, K.H. (Eds.)
    • Green, M.F., & Nuechterlein, K.H. (Eds.). (2004). The MATRICS initiative: Developing a consensus cognitive battery for clinical trials. Schizophrenia Research, 72(1).
    • (2004) Schizophrenia Research , vol.72 , Issue.1
  • 19
    • 4444220908 scopus 로고    scopus 로고
    • Approaching a consensus cognitive battery for clinical trials in schizophrenia: The NIMH-MATRICS conference to select cognitive domains and test criteria
    • Green, M.F., Nuechterlein, K.H., Gold, J.M., Barch, D.M., Cohen, J., Essock, S.,et al.(2004). Approaching a consensus cognitive battery for clinical trials in schizophrenia: The NIMH-MATRICS conference to select cognitive domains and test criteria. Biological Psychiatry, 56, 301-307.
    • (2004) Biological Psychiatry , vol.56 , pp. 301-307
    • Green, M.F.1    Nuechterlein, K.H.2    Gold, J.M.3    Barch, D.M.4    Cohen, J.5    Essock, S.6
  • 20
    • 26444590039 scopus 로고    scopus 로고
    • Social cognition in schizophrenia: Recommendations from the Measurement and Treatment Research to Improve Cognition in Schizophrenia New Approaches conference
    • Green, M.F., Olivier, B., Crawley, J.N., Penn, D.L., & Silverstein, S. (2005). Social cognition in schizophrenia: Recommendations from the Measurement and Treatment Research to Improve Cognition in Schizophrenia New Approaches conference. Schizophrenia Bulletin, 31, 882-887.
    • (2005) Schizophrenia Bulletin , vol.31 , pp. 882-887
    • Green, M.F.1    Olivier, B.2    Crawley, J.N.3    Penn, D.L.4    Silverstein, S.5
  • 21
    • 57749193526 scopus 로고    scopus 로고
    • Perception measurement in clinical trials of schizophrenia: Promising paradigms from CNTRICS
    • Green, M.F., Butler, P.D., Chen, Y., Geyer, M.A., Silverstein, S., Wynn, J.K.,et al.(2009). Perception measurement in clinical trials of schizophrenia: Promising paradigms from CNTRICS. Schizophrenia Bulletin, 35, 163-181.
    • (2009) Schizophrenia Bulletin , vol.35 , pp. 163-181
    • Green, M.F.1    Butler, P.D.2    Chen, Y.3    Geyer, M.A.4    Silverstein, S.5    Wynn, J.K.6
  • 22
    • 26444457491 scopus 로고    scopus 로고
    • Predicting drug efficacy for cognitive deficits in schizophrenia
    • Hagan, J.J., & Jones, D.N. (2005). Predicting drug efficacy for cognitive deficits in schizophrenia. Schizophrenia Bulletin, 31, 830-853.
    • (2005) Schizophrenia Bulletin , vol.31 , pp. 830-853
    • Hagan, J.J.1    Jones, D.N.2
  • 23
    • 7544237332 scopus 로고    scopus 로고
    • Measurement and Treatment Research to Improve Cognition in Schizophrenia: NIMH MATRICS initiative to support the development of agents for improving cognition in schizophrenia
    • Marder, S.R., & Fenton, W. (2004). Measurement and Treatment Research to Improve Cognition in Schizophrenia: NIMH MATRICS initiative to support the development of agents for improving cognition in schizophrenia. Schizophrenia Research, 72, 5-9.
    • (2004) Schizophrenia Research , vol.72 , pp. 5-9
    • Marder, S.R.1    Fenton, W.2
  • 27
    • 64249168387 scopus 로고    scopus 로고
    • Using the MATRICS to guide development of a preclinical cognitive test battery for research in schizophrenia
    • Young, J.W., Powell, S.B., Risbrough, V.B., Marston, H.M., & Geyer, M.A. (2009). Using the MATRICS to guide development of a preclinical cognitive test battery for research in schizophrenia. Pharmacology and Therapeutics, 122, 150-202.
    • (2009) Pharmacology and Therapeutics , vol.122 , pp. 150-202
    • Young, J.W.1    Powell, S.B.2    Risbrough, V.B.3    Marston, H.M.4    Geyer, M.A.5


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.